Abstract
Four thousand, four hundred and forty eligible children of up to 18 years of age were treated in four consecutive trials between 1981 and 1995 with the treatment protocols of the Berlin–Frankfurt–Münster (BFM) study group for childhood acute lymphoblastic leukemia (ALL). The probability for event-free survival (pEFS) at 8 years improved from 65.8% in study ALL-BFM 81 to 75.9% in study ALL-BFM 90. The cumulative incidence of recurrences with CNS involvement was 10.1% and 9.3% in studies ALL-BFM 81 and 83, but was reduced to less than 5% in study ALL-BFM 90 (for isolated CNS relapses from 5.3% in study ALL-BFM 81 to 1.1% in study ALL-BFM 90). Four major findings were derived from this series of trials performed by 37 to 96 centers in Germany, Austria, and Switzerland: (1) Reintensification is a crucial part of treatment, even in low risk patients; (2) presymptomatic cranial radiotherapy can be safely reduced to 12 Gy, or even be eliminated if it is replaced by early intensive systemic and intrathecal methotrexate applied; (3) maintenance therapy given a total of 24 months from diagnosis provides a lower rate of systemic relapses than treatment for 18 months; (4) inadequate response to an initial 7-day prednisone window (combined with one intrathecal injection of methotrexate on day 1) defines about 10% of the patients with a very high risk of relapse. For patients with adequate early response (90% of all) an 8-year pEFS of 80% has been achieved in the most recent trial ALL-BFM 90. While it has proven so far to be impossible to improve the outcome for the small group of high risk patients, the number of recurrences could be effectively reduced for the large group of patients responding adequately to the prednisone in vivo sensitivity test. Apart from inadequate prednisone response, patients with hyperleukocytosis, age <1 year, or the presence of the Philadelphia-chromosome (Ph+ ALL) are at a particularly high risk of failure.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hustu HO, Aur RJ, Verzosa MS, Simone JV, Pinkel D . Prevention of central nervous system leukemia by irradiation Cancer 1973 32: 585–597
Riehm H, Gadner H, Welte K . Die West-Berliner Studie zur Behandlung der akuten lymphoblastischen Leukämie des Kindes – Erfahrungsbericht nach 6 Jahren (The West Berlin therapy study of acute lymphoblastic leukemia in childhood – report after 6 years) Klin Padiatr 1977 189: 89–102
Riehm H, Gadner H, Henze G, Langermann H-J, Odenwald E . The Berlin childhood acute lymphoblastic leukemia therapy study, 1970–1976 Am J Pediatr Hematol Oncol 1980 2: 299–306
Henze G, Langermann HJ, Kaufmann U, Ludwig R, Schellong G, Stollmann B, Riehm H . Thymic involvement and initial white blood count in childhood acute lymphoblastic leukemia Am J Pediatr Hematol Oncol 1981 3: 369–376
Henze G, Langermann H-J, Brämswig J, Breu H, Gadner H, Schellong G, Welte K, Riehm H . Ergebnisse der Studie BFM 76/79 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen (Results of study BFM 76/79 for treatment of acute lymphoblastic leukemia in childhood and adolescence) Klin Pädiatr 1981 193: 145–154
Riehm H, Gadner H, Henze G, Kornhuber B, Langermann H-J, Müller-Weihrich S, Schellong G. Acute lymphoblastic leukemia: treatment results in three BFM studies . 1970–1981 In: Murphy SB, Gilbert JR (eds). Leukemia Research: Advances in Cell Biology and Treatment Elsevier Science: Amsterdam, 1983, pp 251–263.
Langermann H-J, Henze G, Wulf M, Riehm H . Abschätzung der Tumorzellmasse bei der akuten lymphoblastischen Leukämie im Kindesalter: prognostische Bedeutung und praktische Anwendung (Assessment of tumor cell load in acute lymphoblastic leukemia: prognostic significance and practical use) Klin Pädiatr 1982 194: 209–213
Schrappe M, Beck J, Brandeis WE, Feickert HJ, Gadner H, Graf N, Havers W, Henze G, Jobke A, Kornhuber B, Kühl J, Lampert F, Müller-Weihrich S, Niethammer D, Reiter A, Rister M, Ritter J, Schellong G, Tausch W, Weinel P, Riehm H . Die Behandlung der akuten lymphoblastischen Leukämie im Kindes und Jugendalter: Ergebnisse der multizentrischen Therapiestudie ALL-BFM 81 (Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of multicenter trial ALL-BFM 81) Klin Pädiatr 1987 199: 133–150
Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, Reiter A, Schellong G . Results and significance of six randomized trials in four consecutive ALL-BFM trials Hamatol Bluttransfus 1990 33: 439–450
Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein H, Ludwig R, Ritter J, Stollmann B, Henze G . Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) (The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83)) Klin Pädiatr 1987 199: 151–160
Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G, Zimmermann M, Lampert F, Havers W, Niethammer D, Odenwald E, Ritter J, Mann G, Welte K, Gadner H, Riehm H . Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86 Blood 1994 84: 3122–3133
Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M, Schirg E, Henze G, Schellong G, Gadner H, Riehm H . Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report Blood 2000 95: 416–421
Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Hiddemann W, Niemeyer C, Henze G, Feldges A, Zintl F, Kornhuber B, Ritter J, Welte K, Gadner H, Riehm H . Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: results of trial ALL-BFM 90 Blood 2000 95: 3310–3322
Buhrer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G, Henze G . Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin–Frankfurt–Munster Relapse Study Group J Clin Oncol 1996 14: 2812–2817
Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, Riehm H . A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin–Frankfurt–Munster Study Group Blood 1996 87: 3143–3150
Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JWG, Ratei R, Schrappe M, Repp R, Zimmermann M, Kabisch H, Janka-Schaub G, Bartram CR, Ludwig W-D, Riehm H, Lampert F, Harbott J . Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05–92 Leukemia 1996 10: 957–963
Mastrangelo R, Poplack DG, Bleyer WA, Riccardi R, Sather H, D'Angio GJ . Report and recommendations of the Rome Workshop concerning poor-prognosis acute lymphoblastic leukemia in children: biologic bases for staging, stratification, and treatment Med Pediatr Oncol 1986 14: 191–194
Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R . Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia J Clin Oncol 1996 14: 18–24
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C . Proposals for the classification of the acute leukaemias. French–American–British (FAB) cooperative group Br J Haematol 1976 33: 451–458
van der Does van den Berg A, Bartram CR, Basso G, Benoit YC, Biondi A, Debatin KM, Haas OA, Harbott J, Kamps WA, Köller U, Lampert F, Ludwig W-D, Niemeyer CM, van Wering ER . Minimal requirements for the diagnosis, classification, and evaluation of the treatment of childhood acute lymphoblastic leukemia (ALL) in the ‘BFM Family’ Cooperative Group Med Pediatr Oncol 1992 20: 497–505
Ludwig WD, Rieder H, Bartram CR, Heinze B, Schwartz S, Gassmann W, Loffler H, Hossfeld D, Heil G, Handt S, Heyll A, Diedrich H, Fischer K, Weiss A, Volkers B, Aydemir U, Fonatsch C, Gokbuget N, Thiel E, Hoelzer D . Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89 Blood 1998 92: 1898–1909
Creutzig U, Harbott J, Sperling C, Ritter J, Zimmermann M, Löffler H, Riehm H, Schellong G, Ludwig W-D . Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM 87 Blood 1995 86: 3097–3108
European Group for the Immunological Characterisation of Leukaemias (EGIL): Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van't Veer MB . Proposals for the immunological classification of acute leukaemias Leukemia 1995 9: 1783–1786
Harbott J, Ritterbach J, Ludwig W-D, Bartram CR, Reiter A, Lampert F . Clinical significance of cytogenetic studies in childhood acute lymphoblastic leukemia: experience of the BFM trials Recent Results Cancer Res 1993 131: 123–132
Hiddemann W, Wörmann B, Ritter J, Thiel E, Göhde W, Lahme B, Henze G, Schellong G, Riehm H, Büchner T . Frequency and clinical significance of DNA aneuploidy in acute leukemia Ann NY Acad Sci 1986 468: 227–240
Henze G, Langermann H-J, Fengler R, Brandeis M, Evers KG, Gadner H, Hinderfeld L, Jobke A, Kornhuber B, Lampert F, Lasson U, Ludwig R, Müller-Weihrich S, Neidhardt M, Nessler G, Niethammer D, Rister M, Ritter J, Schaaf A, Schellong G, Stollmann B, Treuner J, Wahlen W, Weinel P, Wehinger H, Riehm H . Therapiestudie BFM 79/81 zur Behandlung der akuten lymphoblastischen Leukämie bei Kindern und Jugendlichen: intensivierte Reinduktionstherapie für Patientengruppen mit unterschiedlichem Rezidivrisiko Klin Pädiatr 1982 194: 195–203
Lampert F, Henze G, Langermann H-J, Schellong G, Gadner H, Riehm H . Acute lymphoblastic leukemia: current status of therapy in children Recent Results Cancer Res 1984 93: 159–181
Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481
Mantel N . Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 1966 50: 163–170
Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data John Wiley: New York 1980 pp 163–188
Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 1988 16: 1141–1154
Schrappe M, Reiter A, Welte K, Ludwig W-D, Harbott J, Lampert F, Henze G, Riehm H . Risk adapted treatment in childhood acute lymphoblastic leukemia: data from the Berlin–Frankfurt–Münster Group. In: Büchner T, Hiddemann W, Wörmann B, Schellong G, Ritter J, Creutzig U (eds) Haematology and Blood Transfusion VI: Prognostic Factors and Treatment Strategies Springer: Berlin 1997 pp 601–610
Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM . Treatment of acute lymphoblastic leukemia – 30 years’ experience at St Jude Children's Research Hospital New Engl J Med 1993 329: 1289–1295
Buhrer C, Henze G, Hofmann J, Reiter A, Schellong G, Riehm H . Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials Hamatol Bluttransfus 1990 33: 500–503
Schrappe M, Reiter A, Henze G, Niemeyer C, Bode U, Kühl J, Gadner H, Havers W, Plüss H, Kornhuber B, Zintl F, Ritter J, Urban C, Niethammer D, Riehm H, ALL-BFM Study Group . Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials Klin Pädiatr 1998 210: 192–199
Chessells JM, Bailey C, Richards SM . Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia Lancet 1995 345: 143–148
Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V, Cohen HJ, Sallan SE . Treatment of childhood acutelymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85–01 J Clin Oncol 1994 12: 740–747
Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, Hammond GD . Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial J Clin Oncol 1993 11: 527–537
Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ, Grossman NJ, Novak LJ, Pyesmany AF, Reaman GH, Chappell RJ, Sather HN, Hammond GD . Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106 J Clin Oncol 1993 11: 2234–2242
Veerman AJ, Hahlen K, Kamps WA, van Leeuwen EF, De Vaan GA, Solbu G, Suciu S, van Wering ER, Van der Does-Van der Berg A . High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group J Clin Oncol 1996 14: 911–918
Conter V, Arico M, Valsecchi MG, Rizzari C, Testi AM, Messina C, Mori PG, Miniero R, Colella R, Basso G, Rondelli R, Pession A, Masera G . Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin–Frankfurt–Münster-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica J Clin Oncol 1995 13: 2497–2502
Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M, Mirro JJ, Ochs JS, Look AT, Williams DL, Murphy SB, Dahl GV, Kalwinsky DK, Evans WE, Kun LE, Simone JV, Crist WM . Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy Lancet 1991 337: 61–66
Niemeyer CM, Reiter A, Riehm H, Donnelly M, Gelber RD, Sallan SE . Comparative results of two intensive treatment programs for childhood acute lymphoblastic leukemia: the Berlin–Frankfurt–Munster and Dana-Farber Cancer Institute protocols Ann Oncol 1991 2: 745–749
Conter V, Schrappe M, Arico M, Reiter A, Rizzari C, Dördelmann M, Valsecchi MG, Zimmermann M, Ludwig W-D, Basso G, Masera G, Riehm H . Role of cranial radiotherapy for childhood T cell acute lymphoblastic leukemia with high WBC count and good response to prednisone J Clin Oncol 1997 15: 2786–2791
Löning L, Zimmermann M, Reiter A, Kaatsch P, Henze G, Riehm H, Schrappe M . Secondary neoplasms subsequent to Berlin–Frankfurt–Münster therapy of childhood acute lymphoblastic leukemia: significantly lower risk without cranial radiotherapy Blood 2000 95: 2770–2775
Pui CH, Aur RJ, Bowman WP, Dahl GV, Dodge RK, George SL, Ochs J, Kalwinsky DK, Abromowitch M, Hustu HO . Failure of late intensification therapy to improve a poor result in childhood lymphoblastic leukemia Cancer Res 1984 44: 3593–3598
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS . Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy New Engl J Med 1998 338: 1663–1671
Schrappe M, Reiter A, Riehm H . Prophylaxis and treatment of meningeosis in childhood acute lymphoblastic leukemia J Neurooncol 1998 38: 159–165
Doerdelmann M, Reiter A, Zimmermann M, Fengler R, Henze G, Riehm H, Schrappe M . Intermediate dose methotrexate is as effective as high dose methotrexate in preventing isolated testicular relapse in childhood ALL J Pediatr Hematol Oncol 1998 20: 444–450
Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P, Miller DR, Reaman G, Sather H, Hammond GD . Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features Med Pediatr Oncol 1990 18: 273–279
Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D, Bleyer WA . Cytoreduction and prognosis in acute lymphoblastic leukemia – the importance of early marrow response: report from the Childrens Cancer Group J Clin Oncol 1996 14: 389–398
Schrappe M, Reiter A, Riehm H . Cytoreduction and prognosis in childhood acute lymphoblastic leukemia J Clin Oncol 1996 14: 2403–2406
Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, Crist WM, Pui CH . Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia Blood 1995 86: 1292–1295
Kaspers GJ, Pieters R, Van Zantwijk CH, van Wering ER, van der Does-van den Berg A, Veerman AJP . Prednisolone resistance in childhood acute lymphoblastic leukemia: vitro–vivo correlations and cross-resistance to other drugs Blood 1998 92: 259–266
Griffin TC, Shuster JJ, Buchanan GR, Murphy SB, Camitta BM, Amylon MD . Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study Leukemia 2000 14: 792–795
Galpin AJ, Schuetz JD, Masson E, Yanishevski Y, Synold TW, Barredo JC, Pui CH, Relling MV, Evans WE . Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage vs T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity Mol Pharmacol 1997 52: 155–163
Evans WE, Relling MV . Pharmacogenomics: translating functional genomics into rational therapeutics Science 1999 286: 487–491
Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE . Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus J Natl Cancer Inst 1999 91: 2001–2008
Stanulla M, Schrappe M, Brechlin AM, Zimmermann M, Welte K . Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case–control study Blood 2000 95: 1222–1228
Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V, Reiter A, Valsecchi MG, Gadner H, Basso G, Bartram CR, Lampert F, Riehm H, Masera G . Ph+ childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome Blood 1998 92: 2730–2741
Dördelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehmann S, Gadner H, Riehm H, Schrappe M . Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia Blood 1999 94: 1209–1217
Arico M, Basso G, Mandelli F, Rizzari C, Colella R, Barisone E, Zanesco L, Rondelli R, Pession A, Masera G . Good steroid response in vivo predicts a favorable outcome in children with T-cell acute lymphoblastic leukemia Cancer 1995 75: 1684–1693
Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Reaman GH, Sather HN, Steinherz PG, Trigg ME, Tubergen DG, Uckun FM . Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review Cancer 1997 80: 1717–1726
Hansen-Hagge TE, Yokota S, Bartram CR . Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor chain sequences Blood 1989 74: 1762–1767
Yokota S, Hansen-Hagge TE, Ludwig W-D, Reiter A, Raghavachar A, Kleihauer E, Bartram CR . Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients Blood 1991 77: 331–339
Campana D, Coustan-Smith E, Janossy G . The immunologic detection of residual disease in acute leukemia Blood 1990 76: 163–171
Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H . Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 2000 95: 790–794
van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, Stolz F, Schrappe M, Masera G, Kamps WA, Gadner H, van Wering ER, Ludwig W-D, Basso G, de Bruijn MAC, Cazzaniga G, Hettinger K, van der Does-van den Berg A, Hop WCJ, Riehm H, Bartram CR . Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: a prospective study of the International BFM Study Group Lancet 1998 352: 1731–1738
Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J, Bakkus M, Thielemans K, Grandchamp B, Vilmer E . Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer – Childhood Leukemia Cooperative Group (see comments) New Engl J Med 1998 339: 591–598
Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC, Rubnitz JE, Rivera GK, Sandlund JT, Pui CH, Campana D . Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 1998 351: 550–554
Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G . Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia New Engl J Med 2000 342: 998–1006
Campbell M, Salgado C, Quintana J, Becker A, Vargas L, Cabrera ME, Beresi V, Rojas J, Paez E, Tapia S, Zolezzi P, Advis P . Improved outcome for acute lymphoblastic leukemia in children of a developing country: results of the Chilean National Trial PINDA 87 Med Pediatr Oncol 1999 33: 88–94
Kamps WA, Bökkerink JPM, Hählen K, Hermans J, Riehm H, Gadner H, Schrappe M, Slater R, van den Berg-de Ruiter E, Smets LA, de Vaan GAM, Weening RS, van Weerden JF, van Wering ER, van der Does-van den Berg A . Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM 86 without cranial radiotherapy: results of DCLSG protocol ALL-7 (1988–1991) Blood 1999 94: 1226–1236
Conter V, Arico M, Valsecchi MG, Rizzari C, Testi A, Miniero R, Di Tullio MT, Lo Nigro L, Pession A, Rondelli R, Messina C, Santoro N, Mori PG, De Rossi G, Tamaro P, Silvestri D, Biondi A, Basso G, Masera G . Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica Haematologica 1998 83: 791–799
Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G, Niemeyer CM, Gadner H, Muller Weihrich S, Ritter J, Odenwald E, Riehm H . Favorable outcome of B cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group Blood 1992 80: 2471–2478
Acknowledgements
This work was supported by grants from the Deutsche Leukämieforschungshilfe, the Madeleine Schickedanz Kinderkrebs-Stiftung, and the Deutsche Krebshilfe. The authors thank all data managers, in particular A Nehmer, A Brandt, N Götz, and U Meyer for precise data management, the staff of the reference laboratories for continuous excellent cooperation, the nurses and doctors of all hospitals for their input in performing this study, and the members of the study committee for their contributions during the development of the trials. We thank Jennifer Meyers for proofreading the text. Study committee (study ALL-BFM 90): J Beck, Erlangen; U Bode, Bonn; A Feldges, St Gallen (CH); H Gadner, Wien (A); W Havers, Essen; G Henze, Berlin; A Jobke, Nürnberg; B Kornhuber, Frankfurt; J Kühl, Würzburg; F Lampert, Gießen; R Ludwig, Heidelberg; U Mittler, Magdeburg; C Niemeyer, Freiburg; D Niethammer, Tübingen; H Plüss, Zürich (CH); A Reiter, Hannover; H Riehm, Hannover; J Ritter, Münster; G Schellong, Münster; M Schrappe, Hannover; C Urban, Graz (A); H Wehinger, Kassel; K Welte, Hannover; F Zintl, Jena.
Author information
Authors and Affiliations
Additional information
Dedicated to Professor Günther Schellong, Münster, on the occasion of his 75th birthday on 15 January 2001
Rights and permissions
About this article
Cite this article
Schrappe, M., Reiter, A., Zimmermann, M. et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 14, 2205–2222 (2000). https://doi.org/10.1038/sj.leu.2401973
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401973
Keywords
This article is cited by
-
Targeting autophagy as a therapeutic strategy in pediatric acute lymphoblastic leukemia
Scientific Reports (2024)
-
Dasatinib overcomes glucocorticoid resistance in B-cell acute lymphoblastic leukemia
Nature Communications (2023)
-
Feasibility of Delivering High-Dose Methotrexate in Adolescent and Adult All Patients: A Retrospective Study
Indian Journal of Hematology and Blood Transfusion (2022)
-
Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia
British Journal of Cancer (2020)
-
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia—successful management of two life-threatening diseases
Supportive Care in Cancer (2020)